Superior vena cava defibrillator coils make transvenous lead extraction more challenging and riskier.

[1]  T. Chao,et al.  Statins, risk of diabetes, and implications on outcomes in the general population. , 2012, Journal of the American College of Cardiology.

[2]  J. Neuzner,et al.  Dual- versus single-coil implantable defibrillator leads: review of the literature , 2012, Clinical Research in Cardiology.

[3]  Anil . Kumar,et al.  Abstract 17919: Defibrillation Thresholds in Single Versus Dual Coil ICD Lead Systems: Is There Any Difference? , 2011 .

[4]  C. Albert,et al.  Multicenter experience with extraction of the Sprint Fidelis implantable cardioverter-defibrillator lead. , 2010, Journal of the American College of Cardiology.

[5]  L. Epstein,et al.  Transvenous lead extraction: Heart Rhythm Society expert consensus on facilities, training, indications, and patient management: this document was endorsed by the American Heart Association (AHA). , 2009, Heart rhythm.

[6]  W. Elliott,et al.  Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis , 2007, The Lancet.

[7]  R. Collins,et al.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri , 2005, The Lancet.

[8]  L. Lind,et al.  Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study , 2003, BMJ : British Medical Journal.

[9]  G. Mancia,et al.  INSIGHT: international nifedipine GITS study intervention as a goal in hypertension treatment. , 1996, Journal of human hypertension.